Quest Diagnostics INC 8-K filings

Quest Diagnostics reported strong second quarter 2026 financial results, exceeding expectations with significant revenue and EPS growth, and consequently raised its full-year financial outlook.

Quest Diagnostics Incorporated held its 2026 Annual Meeting of Stockholders on May 20, 2026, where shareholders voted on director elections, executive compensation, and auditor ratification.

Quest Diagnostics has successfully issued $500 million in senior notes due 2036 to support general corporate purposes.

Quest Diagnostics has priced a $500 million offering of 5.000% senior notes due 2036 to be used for general corporate purposes, including potential debt repayment.

Quest Diagnostics reported strong first-quarter 2026 financial results, exceeding expectations with significant revenue and EPS growth, leading to an upward revision of full-year guidance.

Quest Diagnostics announced the election of Timothy Wentworth, former CEO of Walgreens Boots Alliance, to its Board of Directors, enhancing its leadership with extensive healthcare and operational expertise.

Quest Diagnostics reported robust fourth-quarter and full-year 2025 financial results, alongside a 7.5% dividend increase and an additional $1 billion share repurchase authorization.

Quest Diagnostics presented its strategy for sustainable growth and long-term value at the 44th Annual J.P. Morgan Healthcare Conference, highlighting market position, operational improvements, and financial outlook.

Quest Diagnostics reported robust third-quarter 2025 financial results, with revenues up 13.1% and adjusted diluted EPS up 13.0%, leading to an upward revision of its full-year 2025 guidance.

Quest Diagnostics Incorporated announced robust second-quarter 2025 financial results, including a 15.2% revenue increase and 11.5% adjusted EPS growth, leading to an upward revision of its full-year 2025 financial guidance.

Quest Diagnostics held its 2025 Annual Meeting of Stockholders on May 15, 2025, and announced the voting results for the election of directors, executive compensation, appointment of the independent accounting firm, and a stockholder proposal.

Quest Diagnostics announced a 12.1% increase in first-quarter revenue and reaffirmed its full-year 2025 revenue and adjusted diluted EPS guidance.

Quest Diagnostics outlines its plans for sustainable growth and long-term shareholder value, targeting a 4%-5% revenue CAGR and 7%-9% adjusted EPS CAGR beyond 2025.

Quest Diagnostics reaffirms its 2025 guidance and unveils its long-term growth strategy, projecting a 4-5% revenue CAGR and a 7-9% adjusted EPS CAGR beyond 2025.

Quest Diagnostics announced a 14.5% increase in fourth-quarter revenue and a 6.7% increase in full-year revenue, along with an increased dividend and positive guidance for 2025.

Quest Diagnostics announced a strong third quarter with revenue growth of 8.5% and updated its full-year 2024 revenue guidance upwards.

Quest Diagnostics has completed its acquisition of LifeLabs Inc., a Canadian provider of laboratory diagnostic information and digital health connectivity systems.

Quest Diagnostics has priced a $1.85 billion offering of senior notes to fund its acquisition of LifeLabs and for general corporate purposes.

Quest Diagnostics announced a 2.5% revenue increase in the second quarter of 2024, along with an improved full-year outlook.

Quest Diagnostics has agreed to acquire LifeLabs for approximately $985 million USD, marking a significant expansion of its diagnostic services in Canada.

Quest Diagnostics has elected Robert B. Carter, Executive Vice President and Chief Information Officer of FedEx Corporation, to its Board of Directors.

Quest Diagnostics amended its Restated Certificate of Incorporation to exculpate officers and elected directors at its annual meeting on May 16, 2024.

Quest Diagnostics announced a 1.5% revenue increase in Q1 2024 and raised its full-year revenue and adjusted earnings guidance.

Quest Diagnostics reported a decrease in full-year revenue but an increase in fourth-quarter earnings per share, while also raising its quarterly dividend and providing guidance for 2024.